Carimune Nanofiltered Being Discontinued
June 15, 2018 – CSL Behring has announced its intention to discontinue production of Carimune® Immune Globulin Intravenous (Human), Nanofiltered, in the third quarter of 2018.
The product has been on the market in the United States since 1984. Over time, prescriber preferences have shifted to newer and more advanced immune globulin products. Due to this market shift, CSL Behring has elected to halt production of Carimune Nanofiltered in order to focus on other intravenous immune globulin products.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.